Cervical Cancer

314

Pipeline Programs↗

150

Active Trials↗

96

Companies Involved↗

Cervical Cancer is a highly competitive landscape with 314 programs across 96 companies. The most active players are EMD Serono Research & Development Institute, Inc., Shanghai OriginCell Therapeutics Co., Ltd., Hookipa Biotech GmbH. 15 therapies are approved with 73 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

89/100

Pipeline Velocity

64/100

Mech. Concentration

8/100

Completion Rate

70/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

EMD Serono Research & Development Institute, Inc.

2 programs

Shanghai OriginCell Therapeutics Co., Ltd.

1 program

Hookipa Biotech GmbH

1 program

Agouron Pharmaceuticals

1 program

Takeda

1 program

Changchun GeneScience Pharmaceutical Co., Ltd.

1 program

Pipeline

Programs by Phase

Preclinical34

Misoprostol

Pfizer

Cemiplimab

Regeneron

Indocyanine Green

CHX Technologies Inc.

Incobotulinumtoxina

Merz Pharmaceuticals GmbH

Avelumab

EMD Serono

Phase 129

Bintrafusp Alfa

EMD Serono Research & Development Institute, Inc.

Riboflavin

Cornea and Laser Eye Institute

Tegafur

The First Affiliated Hospital with Nanjing Medical University

Erlotinib

Dutch Society of Physicians for Pulmonology and Tuberculosis

Nelfinavir

Agouron Pharmaceuticals

Phase 2163

Nivolumab

Bristol-Myers Squibb

Pemetrexed Disodium

Gynecologic Oncology Group

Curcumin

Merck & Co.

Dostarlimab

Glaxo Dba Glaxosmithkline

Eribulin Mesylate

Eisai

Phase 373

Pembrolizumab

Merck & Co.

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Serplulimab

Shanghai Henlius Biotech

Zimberelimab

Arcus Biosciences

Nimotuzumab

Biotech Pharmaceutical Co., Ltd.

Approved15

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Ondansetron

Novartis

Granisetron

Conrado Roberto Hoffmann Filho

Capivasertib

AstraZeneca

Eflornithine

USWM, LLC (dba US WorldMeds)

Analysis

Modality Breakdown

76%

Small molecule

259 of 339 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 339 classified programs, each share of the total. Modality classified for 99% of 381 pipeline programs.

Analysis

Trial Status

450

clinical trials

Completed138 · 31%

Unknown status101 · 22%

Recruiting82 · 18%

Not yet recruiting39 · 9%

Terminated37 · 8%

Active, not recruiting28 · 6%

Other25 · 6%

Clinical Trials

Trial Activity

450 trials

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06925724·50 enrolled

Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)

Recruiting·VVall d'Hebron Institute of Oncology·Phase 2·NCT06630611·40 enrolled

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06459180·686 enrolled

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT06155396·116 enrolled

Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer

Recruiting·HHospital do Coracao·Phase 3·NCT05764044·365 enrolled

Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

Recruiting·UUniversity Hospital, Toulouse·Phase 3·NCT03534713·310 enrolled

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Recruiting·SShandong University·Phase 2·NCT06251947·83 enrolled

Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT07104149·29 enrolled

Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06511726·29 enrolled

Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)

Recruiting·FFujian Cancer Hospital·Phase 2·NCT07055399·43 enrolled

Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study

Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT04583254·48 enrolled

Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer

Recruiting·OObstetrics & Gynecology Hospital of Fudan University·Phase 2·NCT07130240·20 enrolled

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT07051486·60 enrolled

Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients

Recruiting·RRuijin Hospital·Phase 3·NCT05277688·340 enrolled

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06942416·36 enrolled

Page 1 of 30

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)